Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
by WRAL TechWire May 26, 2021 .
DURHAM –Inhalon Biopharma is developing a “muco-trapping” antibody platform that could be used to treat acute respiratory infections, including COVID-19, and the Durham-based startup has now been awarded a $7 million contract by the United States Army Medical Research & Development Command (USAMRDC).
The contract will allow the company to conduct a placebo-controlled Phase 1 and Phase 2a study of its technology in COVID-19 outpatients, the company shared in a statement.
The technology, currently designated IN-006, is described by the company as a potent, neutralizing monoclonal antibody that is being investigated as a possible treatment for COVID-19.
The company expects results of the study in 2022.